Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMANASDAQ:AUTLNASDAQ:GRTSNASDAQ:NKNASDAQ:STRO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$18.05-1.3%$20.24$10.21▼$25.67$4.31B0.433.15 million shs616,618 shsAUTLAutolus Therapeutics$2.30-3.2%$1.81$1.11▼$5.00$610.79M1.811.58 million shs1.36 million shsGRTSGritstone bio$0.35$0.03▼$3.17$3.50M0.497.01 million shs61.02 million shsNKNantKwest$2.72+3.0%$28.01$2.52▼$45.42$297.42M2.611.57 million shs3.28 million shsSTROSutro Biopharma$0.74-2.6%$0.87$0.52▼$5.17$63.09M1.641.14 million shs367,086 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics0.00%+0.74%-11.23%-0.57%+59.64%AUTLAutolus Therapeutics0.00%+2.60%+1.28%+80.92%-31.30%GRTSGritstone bio0.00%0.00%0.00%0.00%-94.45%NKNantKwest0.00%+0.74%-6.21%-8.42%-57.23%STROSutro Biopharma0.00%+4.22%-9.79%+6.62%-73.80%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMAADMA Biologics4.1602 of 5 stars3.72.00.00.03.02.53.1AUTLAutolus Therapeutics2.546 of 5 stars3.51.00.00.01.93.30.6GRTSGritstone bioN/AN/AN/AN/AN/AN/AN/AN/ANKNantKwestN/AN/AN/AN/AN/AN/AN/AN/ASTROSutro Biopharma3.1947 of 5 stars3.11.00.04.70.61.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMAADMA Biologics 3.33Buy$27.6751.23% UpsideAUTLAutolus Therapeutics 3.00Buy$9.32293.25% UpsideGRTSGritstone bio 2.50Moderate Buy$2.17∞ UpsideNKNantKwest 0.00N/AN/AN/ASTROSutro Biopharma 2.25Hold$6.11699.25% UpsideCurrent Analyst Ratings BreakdownLatest STRO, GRTS, AUTL, NK, and ADMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2025STROSutro BiopharmaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight$2.006/12/2025AUTLAutolus TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.005/19/2025STROSutro BiopharmaBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderperform ➝ Underperform$1.00 ➝ $0.805/8/2025ADMAADMA BiologicsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetStrong-Buy ➝ Strong-Buy$25.00 ➝ $32.004/29/2025STROSutro BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$2.00 ➝ $2.004/10/2025AUTLAutolus TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMAADMA Biologics$426.45M10.24$0.54 per share33.77$1.48 per share12.36AUTLAutolus Therapeutics$10.12M62.33N/AN/A$1.61 per share1.47GRTSGritstone bio$496K0.00N/AN/A$0.54 per share0.00NKNantKwest$40K7,435.46N/AN/A$1.23 per share2.21STROSutro Biopharma$62.04M1.04N/AN/A$0.54 per share1.42Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMAADMA Biologics$197.67M$0.8521.5226.51N/A45.01%47.16%30.51%8/6/2025 (Estimated)AUTLAutolus Therapeutics-$220.66M-$0.88N/AN/AN/AN/A-52.82%-29.67%8/8/2025 (Estimated)GRTSGritstone bio-$138.49M-$1.24N/AN/AN/A-910.50%-328.51%-82.53%N/ANKNantKwest-$65.79M-$0.70N/AN/AN/A-76,658.58%-56.06%-46.93%N/ASTROSutro Biopharma-$227.46M-$2.98N/AN/AN/A-373.66%-347.60%-59.46%8/12/2025 (Estimated)Latest STRO, GRTS, AUTL, NK, and ADMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025AUTLAutolus Therapeutics-$0.24-$0.26-$0.02-$0.26$1.59 million$8.98 million5/8/2025Q1 2025STROSutro Biopharma-$0.63-$0.91-$0.28-$0.91$11.61 million$17.40 million5/7/2025Q1 2025ADMAADMA Biologics$0.16$0.14-$0.02$0.11$116.40 million$114.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMAADMA BiologicsN/AN/AN/AN/AN/AAUTLAutolus TherapeuticsN/AN/AN/AN/AN/AGRTSGritstone bioN/AN/AN/AN/AN/ANKNantKwestN/AN/AN/AN/AN/ASTROSutro BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMAADMA Biologics0.226.583.36AUTLAutolus TherapeuticsN/A9.249.02GRTSGritstone bio1.832.542.54NKNantKwestN/A4.744.74STROSutro BiopharmaN/A2.162.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMAADMA Biologics75.68%AUTLAutolus Therapeutics72.83%GRTSGritstone bio48.46%NKNantKwest9.38%STROSutro Biopharma96.99%Insider OwnershipCompanyInsider OwnershipADMAADMA Biologics3.70%AUTLAutolus Therapeutics25.70%GRTSGritstone bio4.61%NKNantKwest71.73%STROSutro Biopharma5.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMAADMA Biologics530238.73 million229.90 millionOptionableAUTLAutolus Therapeutics330266.14 million197.74 millionOptionableGRTSGritstone bio190108.57 million111.84 millionOptionableNKNantKwest160109.35 millionN/ANot OptionableSTROSutro Biopharma24084.46 million79.48 millionOptionableSTRO, GRTS, AUTL, NK, and ADMA HeadlinesRecent News About These CompaniesSutro Biopharma (NASDAQ:STRO) Upgraded by Piper Sandler to Overweight RatingJune 16, 2025 | marketbeat.comSutro Biopharma, Inc. (NASDAQ:STRO) Given Consensus Rating of "Hold" by AnalystsJune 16, 2025 | marketbeat.comSutro Biopharma upgraded to Overweight from Neutral at Piper SandlerJune 16, 2025 | msn.comSutro Biopharma, Inc. (NASDAQ:STRO) Shares Sold by Millennium Management LLCJune 7, 2025 | marketbeat.comSutro Biopharma Appoints Greg Chow as Chief Financial OfficerJune 2, 2025 | finance.yahoo.comSutro Biopharma, Inc.: Sutro Biopharma Reports First Quarter 2025 Financial Results and Business HighlightsMay 9, 2025 | finanznachrichten.deSutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue EstimatesMay 8, 2025 | zacks.comSutro Biopharma Reports First Quarter 2025 Financial Results and Business HighlightsMay 8, 2025 | globenewswire.comSutro Biopharma to Participate in Upcoming Investor ConferencesMay 1, 2025 | globenewswire.comWhy Sutro Biopharma, Inc.’s (STRO) Stock Is Down 21.92%April 26, 2025 | aaii.comAWhy Sutro Biopharma, Inc.’s (STRO) Stock Is Down 10.88%April 1, 2025 | aaii.comAWhy Sutro Biopharma, Inc.’s (STRO) Stock Is Up 15.10%March 18, 2025 | aaii.comASutro Biopharma downgraded to Neutral from Buy at H.C. WainwrightMarch 17, 2025 | markets.businessinsider.comHC Wainwright & Co. Downgrades Sutro Biopharma (STRO)March 17, 2025 | msn.comSutro Biopharma presents expanded data from REFRalphaME-01 trialMarch 16, 2025 | markets.businessinsider.comSutro Biopharma Presents Data from Dose-Optimization Portion of REFRaME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025March 15, 2025 | tmcnet.comSutro Biopharma Presents Data from Dose-Optimization Portion of REFRaME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025March 15, 2025 | tmcnet.comSutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025March 15, 2025 | globenewswire.comWhy Sutro Biopharma, Inc.’s (STRO) Stock Is Down 35.19%March 15, 2025 | aaii.comAWedbush Downgrades Sutro Biopharma (STRO)March 15, 2025 | msn.comSutro Biopharma downgraded to Neutral from Overweight at Piper SandlerMarch 14, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military Spend3 AI Infrastructure Stocks With Strong Growth, Not HypeBy Chris Markoch | June 26, 2025View 3 AI Infrastructure Stocks With Strong Growth, Not HypeChime’s Smart IPO: Half the Valuation, Double the StrengthBy Jeffrey Neal Johnson | June 18, 2025View Chime’s Smart IPO: Half the Valuation, Double the StrengthThese 3 Dividend Stocks Combine Strong Yields With UpsideBy Chris Markoch | June 20, 2025View These 3 Dividend Stocks Combine Strong Yields With UpsideSTRO, GRTS, AUTL, NK, and ADMA Company DescriptionsADMA Biologics NASDAQ:ADMA$18.05 -0.23 (-1.26%) As of 01:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Autolus Therapeutics NASDAQ:AUTL$2.30 -0.08 (-3.16%) As of 01:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.Gritstone bio NASDAQ:GRTSGritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.NantKwest NASDAQ:NKNantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's N-801 and/or N-803 products; collaboration with Be The Match BioTherapies for the development of cell therapy to prevent COVID-19 deaths; and strategic alliance with Immunitybio. It also has a collaboration with CBR Systems, Inc. to develop a COVID-19 treatment leveraging newborn stem cells. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.Sutro Biopharma NASDAQ:STRO$0.74 -0.02 (-2.65%) As of 01:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Warehouse Wars: Can BJ’s Take Advantage of Costco’s Weakness? Why Freeport-McMoRan Is The Copper King in a Tight Market Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
